Fineotex Chemical Ltd

- Fineotex recently commissioned a new state-of-the-art plant at Ambernath, addressing organic growth needs. - Additional capex expected to be moderate, around INR 10-40 crores in the near term for organic expansion. - Further investments for CrudeChem’s capacity expansion and R&D planned, totaling less than INR 70-80 crores (under $10 million) over 1.5 to 2 years. - CrudeChem is currently debt-free, and Fineotex intends to maintain a disciplined, debt-free capital deployment strategy. - Long-term strategy includes leveraging existing cash flows and internal accruals to fund these expansions without incurring debt. - The company remains open to inorganic growth opportunities, supported by a healthy cash balance and robust financial flexibility.

- The company expects significant revenue growth driven by multiple segments including textiles, oil & gas, and cleaning & hygiene. - Textile segment: Orders have doubled recently with tariff reductions in the U.S., signaling an uptick in demand and expected boom after muted growth in prior quarters. - Oil & gas (CrudeChem): Expansion plans underway with capacity and R&D spending of under $10M over 1.5-2 years; the segment is poised for rapid growth with new strategic tie-ups and increased exploration activities globally. - Overall, Fineotex aims to become a INR1,000+ crores company in the next financial year, with a medium-term goal of $200 million revenue by 2030 from a base of around $65 million. - Volume growth is strong, with a 39% year-on-year increase in Q3 volumes, driven by new customers and expanded product lines. - Capacity utilization currently at 64%, with room to scale up production without massive new capex immediately. - Management remains confident of continued expansion and margin improvement going forward.

- Fineotex expects robust long-term growth driven by innovation and operational synergies post-acquisitions. - The company aims to become a INR1,000 crore+ revenue firm next financial year and targets $200 million (INR1,800 crores) revenue by 2030. - Textile segment volumes are increasing with expected improved order books due to easing tariffs and increased demand. - The acquisition of CCT and CrudeChem businesses is expected to improve margins, with CrudeChem projected to achieve double-digit EBITDA margins going forward. - Capex plans are moderate (INR10-40 crores) focusing on organic growth and efficient capacity utilization (~64% currently). - Integration benefits and expansion in oil & gas and textile segments should drive volume and margin improvement. - The company maintains a debt-free status, supporting disciplined cash deployment for growth. - Earnings outlook is optimistic with a 39% YoY volume increase in Q3 and expected continued momentum.

- Textile segment is witnessing an uptick in order books, especially from Indian textile companies supplying to the U.S. market. - Orders have doubled recently after import tariff resolutions, signaling growing demand. - Major customers like Himatsingka, Indo Count, Vardhman, and Gokaldas are gearing up for increased supplies. - Companies in the textile industry are considering expansions over the next 2 years, indicating positive outlook. - Cleaning and hygiene segment is stabilizing with new products, expanded sales teams, and bigger accounts being secured. - Oil and gas specialty chemicals, including CrudeChem, are seeing growth with ongoing expansions and strategic tie-ups. - Overall, management expects robust order inflows across segments, with order books strengthening, especially in textiles and oilfield chemicals.

- During the quarter, the company received approximately INR35.68 crores through the conversion of 75% of outstanding warrants, including INR17.3 crores from the promoter, indicating equity fundraising via warrants. - There is no mention of any new debt raising; the management emphasized that the CrudeChem acquisition is a debt-free company. - The company intends to remain debt-free going forward, maintaining financial discipline. - Capex and expansion plans will be funded through internal accruals and existing cash flows without significant new borrowings. - Overall, no fresh major fundraising through debt is planned, while minor equity infusion happened through warrant conversion recently.